Lessons learned from candidate drug attrition

IDrugs

Volumn 13, Issue 12, 2010, Pages 869-873

  Empfield, James R ^a   Leeson, Paul D ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Clinical trial design; drug attrition; pharmacokinetics; physical property; R D productivity; safety

Indexed keywords

DRUG;

COMBINATORIAL CHEMISTRY; DRUG EXPOSURE; DRUG INDUSTRY; DRUG METABOLISM; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG SOLUBILITY; DRUG SPECIFICITY; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; PHYSICAL CHEMISTRY; REVIEW; TOXICITY TESTING;

ANIMALS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; EFFICIENCY, ORGANIZATIONAL; HUMANS; MODELS, ORGANIZATIONAL; PHARMACOKINETICS; RESEARCH DESIGN;

EID: 79952747781     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov (2004) 3(8):711-715. (Pubitemid 39173511)
2. Schuster D, Laggner C, Langer T: Why drugs fail-A study on side effects in new chemical entities. Curr Pharm Des (2005) 11(27):3545-3559. (Pubitemid 41300759)
3. Munos B: Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov (2009) 8(12):959-968.
4. Paul SM, Mytelka DS Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL: How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat Rev Drug Discov (2010) 9(3):203-214.
5. Wenlock MC, Austin RP, Barton P, Davis, AM, Leeson PD: A comparison of physiochemical property profles of development and marketed oral drugs. J Med Chem (2003) 46(7):1250-1256. (Pubitemid 36428230)
6. Leeson PD, Springthorpe B: The infuence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov (2007) 6(11):881-890. (Pubitemid 350042396)
7. Price DA, Blagg J, Jones L, Greene N, Wagner T: Physicochemical drug properties associated with in vivo toxicological outcomes: A review. Expert Opin Drug Metab Toxicol (2009) 5(8):921-931.
8. Cartwright ME, Cohen S, Fleishaker JC, Madani S, McLeod JF, Musser B, Williams SA: Proof of concept: A PhRMA position paper with recommendations for best practice. Clin Pharm Ther (2010) 87(3):278-285.
9. Woodcock J: Precompetitive research: A new prescription for drug development? Clin Pharm Ther (2010) 87(5):521-523.
10. Fryburg DA: Do technical and commercial biases contribute to the pharmaceutical industry's productivity problems? An analysis of how reordering priorities can impact productivity. Drug Discov Today (2010) 15(17-18):766-772.
11. Wehling M: Assessing the translatability of drug projects: What needs to be scored to predict success? Nat Rev Drug Disc (2009) 8(7):541-546.